Company CVAbout Marksans Pharma Ltd 
Marksans Pharma Ltd
Mid Cap
Pharmaceuticals & Drugs
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.
Company Coordinates
Company Details
11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) Mumbai Maharashtra : 400053
Registrar Details
Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 45.32 Cr
Number of Shares
45.32 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
20-Jan-2023
45.32
45.32
50324324
1
Conversion of Warrants
17-Jan-2023
40.28
40.28
-124692
1
Buy Back of Shares
10-Jan-2023
40.3
40.30
-70000
1
Buy Back of Shares
19-Dec-2022
40.3
40.30
-3323251
1
Buy Back of Shares
30-Sep-2022
40.64
40.64
-2956333
1
Buy Back of Shares
30-Mar-2015
40.93
40.93
24006494
1
QIB Equity Shares
30-Mar-2015
40.93
40.93
24006494
1
QIB Equity Shares
14-Dec-2012
38.53
38.53
17500000
1
Conversion of Warrants
14-Dec-2012
38.53
38.53
17500000
1
Conversion of Warrants
14-Apr-2010
36.78
36.78
1333
1
FCCB
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 9 Schemes (3.15%)
FIIs
Held by 130 FIIs (21.96%)
Promoter with highest holding
Mark Saldanha (43.8%)
Highest Public shareholder
Orbimed Asia Iv Mauritius Fvci Limited (10.88%)
Individual Investors Holdings
26.24%
Board of Directors
Management
Designation
Remuneration
Mark Saldanha
Chairman & Managing Director
5.22 cr
Harshavardhan Panigrahi
Company Sec. & Compli. Officer
0
Seetharama Raju Buddharaju
Non-Exec. & Independent Dir.
40.0 k
Sandra Saldanha
Whole-time Director
70.3 lacs
Digant Mahesh Parikh
Non-Exec. & Independent Dir.
2.0 lacs
Varddhman Vikramaditya Jain
Whole-time Director
1.52 cr
Abhinna Sundar Mohanty
Non-Exec. & Independent Dir.
40.0 k
Sunny Sharma
Director
0
Shailaja Vardhan
Independent Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Purchases
30.90669
0%
Purchases
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Export Incentives
11.43
2.69%
Export Incentives
Export Incentives
Stock DNARevenue and Profits:
Net Sales:
682 Cr
(Quarterly Results - Dec 2024)
Net Profit:
105 Cr
Pharmaceuticals & Drugs
INR 9,247 Cr (Mid Cap)
24.00
33
0.31%
-0.21
15.21%
3.86
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
